Tech Company Financing Transactions
ACT Genomics Funding Round
CDIB Bioscience, Hotung Capital Management and Eminent Venture Capital participated in a $12.5 million Series B funding round for ACT Genomics. The financing was announced on 5/6/2016.
Transaction Overview
Company Name
Announced On
5/6/2016
Transaction Type
Venture Equity
Amount
$12,500,000
Round
Series B
Investors
CDIB Bioscience (Lead Investor)
Hotung Capital Management (Lead Investor)
Proceeds Purpose
ACT Genomics plans to use the proceeds to further boost the capacity to support the rapid growth and expansion in Japan, Taiwan, Singapore, Malaysia, Thailand, and Hong Kong.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
No. 280 Xinhu 2nd Rd. Neihu Dist. 1F
Taipei, 114
Taiwan
Taipei, 114
Taiwan
Phone
Website
Email Address
Overview
Founded in 2014, ACT Genomics is a cancer molecular information service company teamed up with experts with multiple years' experience in oncology, cancer genomics, and bioinformatics. The company's technology provides the possibility to transform cancer genomic information into precision diagnosis and personalized treatments.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Hua Chen
Chief Financial Officer
Victor Chan
Chief Operating Officer
Joe Hsueh
Chief Scientific Officer
Shu Chen
Vice President
Allen Lai
Browse more venture capital transactions:
Prev: 5/6/2016: YieldStreet venture capital transaction
Next: 5/6/2016: Drawbridge venture capital transaction
Share this article
Where The Data Comes From
We do our best to document every notable VC transaction. VC investment data records on this site are derived from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs